Trial Profile
A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Apr 2020
Price :
$35
*
At a glance
- Drugs Gilteritinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 18 Apr 2020 Results published in the Clinical Pharmacokinetics
- 20 Jul 2017 Status changed from active, no longer recruiting to completed.
- 12 Jun 2017 Planned End Date changed from 27 May 2017 to 1 Jun 2017.